TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02725359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Group Placebo: will receive a placebo pill 1 hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group Placebo: will receive a placebo pill 1 hour before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Group T: 6 mg tizanidine1 hour before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: USG guided SCPB with saline bilaterally 10 ml each side
Study: NCT03612453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
Study: NCT01976156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhosphoLean
Description: PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of rice flour
Study: NCT00995618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: Tranilast tablets, 300 mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: Febuxostat Tablets, 40 mg, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination - Tranilast and Febuxostat
Description: Tranilast, 300 mg QD; Febuxostat, 40 mg QD
Study: NCT03359187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline with salt/Soda
Description: Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinacanthus nutans
Description: Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boesenbergia rotunda
Description: Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
Study: NCT04502888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SL-172154
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study: NCT01248078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keflex
Description: 2g of i.v. cefazolin singleshot administered before skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keflex
Description: 2g of i.v. cefazolin singleshot administered after umbilical cord clamping

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 100cc administered before skin incision
Study: NCT00027963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03709485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rectal swab for microbial culture.
Description: Rectal swab and culture.
Study: NCT00873678

Intervention type: BIOLOGICAL
Intervention: Whole blood sample
Description: Whole blood sample (10 ml)
Study: NCT04581356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: daily voxelotor 1500mg oral medication
Study: NCT04277442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT02001207

Intervention type: OTHER
Intervention: Salivary cortisol test
Study: NCT02522299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557
Description: GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS
Description: It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DISKUS
Description: It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ELLIPTA
Description: It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
Study: NCT01050699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam and Fentanyl
Description: Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)
Study: NCT02430597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT03029611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gynecological Surgical Procedure
Description: Undergo cytoreductive surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
Description: Given ID
Study: NCT03987672

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula
Description: Kate Farm Peptide 1.5 nutritional Formula
Study: NCT01532024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microdose of NAP
Description: Delivery of NAP at microdose (\<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microdose of NAP
Description: Delivery of NAP at microdose (\<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
Study: NCT02517359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 14 day repeat dose
Description: Safety and tolerability of repeat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 matching placebo 14 day repeat dose
Description: Safety and tolerability of repeat doses
Study: NCT00942578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 intravenous (IV) over 60 minutes on cycle 1 day 1, repeated every 21 days (a 3-week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10 mg orally every day
Study: NCT02517359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 matching placebo 14 day repeat dose
Description: Safety and tolerability of repeat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 matching placebo 14 day repeat dose
Description: Safety and tolerability of repeat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 28 day repeat dose
Description: Safety and tolerability of repeat doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 matching placebo 28 day repeat dose
Description: Safety and tolerability of repeat doses
Study: NCT02896868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study: NCT03961776

Intervention type: DEVICE
Intervention: MRI-guided radiotherapy by on-board DWI sequences
Description: The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.
Study: NCT02758054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Patient navigated reminder calls containing information about screening appointments, reminders, hints to facilitate communication with physicians, and smoking cessation.
Study: NCT01023269

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim Therapy
Description: Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim Therapy
Description: Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.
Study: NCT03080194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Subject in control group will be applied with oral antipsychotics or other conventional medication.
Study: NCT02400710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician-Supported PTSD Coach
Description: Brief primary care-based intervention provided by a mental health clinician who is located in primary care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Managed PTSD Coach
Description: One 10 minute session explaining how to use the PTSD Coach mobile app.
Study: NCT03137082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine XR 3mgs/daily
Description: Guanfacine 3mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for guanfacine)
Description: Sugar pill manufactured to mimic guanfacine tablets
Study: NCT00417599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: lifestyle intervention .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: waiting list control group
Study: NCT02922959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Intervention
Description: The Peer Intervention is a 20-minute telephone call delivered by a Peer Interventionist, who is trained to answer questions about the content of the personally-tailored information packets. The primary goal of the call is for the participant and the Peer Interventionist to have an open exchange of information about medication-assisted treatment (MAT) for opioid use disorder.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone nasal spray kit
Description: Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone nasal spray kit
Description: Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personally-tailored opioid overdose prevention education (information packet)
Description: Personally-tailored information packet with three participant-specific reports (Personal Overdose Risk Factors Report; Medication Assisted Treatment (MAT) Report; and the Opioid Overdose Information Report), and general written information about opioid overdose and treatment for opioid use disorder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personally-tailored opioid overdose prevention education (information packet)
Description: Personally-tailored information packet with three participant-specific reports (Personal Overdose Risk Factors Report; Medication Assisted Treatment (MAT) Report; and the Opioid Overdose Information Report), and general written information about opioid overdose and treatment for opioid use disorder.
Study: NCT04898725

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 4800IU daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 4800IU daily
Study: NCT01928784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy 2000 impulses
Description: Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy 4000 impulses
Description: Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
Study: NCT01779947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Tablets 10 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Vaginal Tablets 10 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03348982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jogging program
Description: The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session).
Study: NCT02200133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Survivorship Care Plan (SCP)
Description: The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
Study: NCT00887627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan hydrochloride
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan hydrochloride
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan hydrochloride
Description: intravenous
Study: NCT04486183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: capillary blood samples
Description: The patient's finger was wiped with alcohol, left to dry, and the first and second blood drops were read The patient was asked to wash their hands, their finger was perforated with a strip, and the first and second blood drops were read The finger of the patient whose hands had been washed was wiped with alcohol, left to dry, and the first and second blood drops were read Venous blood was collected for blood sugar measurement 2 hours after the patient had a beverage containing 75 gr sugar for OGTT The patient was ensured to wash their hands, their finger was wiped with alcohol, and the first and second blood drop glucose values were measured and recorded
Study: NCT02439606

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glide Rite Rigid Stylet group
Description: Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parker Flex-It directional stylet group
Description: Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
Study: NCT01532024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microdose of NAP
Description: Delivery of NAP at microdose (\<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
Study: NCT03140306

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patients who have had split dose CT
Description: Computed tomography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patients who have had split dose CT
Description: Computed tomography
Study: NCT02208583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel & Prednisone
Description: Docetaxel \& Prednisone: Docetaxel 75mg/m2，d1;Prednisone 5mg，bid，d1-21

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DP & Targeted drugs
Description: Docetaxel 75mg/m2，d1; Prednisone 5mg，bid，d1-21;Targeted drugs for PO. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin & Etoposide
Description: cisplatin \& Etoposide:cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EP & Targeted drugs
Description: cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3; Targeted drugs for po. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
Study: NCT03361514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Protocolized Discontinuation (SPD)
Description: Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supported Protocolized Discontinuation (SPD)
Description: Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Description: In addition to the SPD patients are offered Mindfulness Based Cognitive Therapy (MBCT) in homogeneous groups of patients willing to withdraw from their medication. MBCT will be offered according to the treatment protocol developed for recurrent depression, adaptated to the specific needs of patients discontinuing their antidepressant medication. The mindfulness courses will be provided by teachers qualifying the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders. All teachers will receive additional training in using the specific study protocol at the start of the project.